Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 98 results for bevacizumab

  1. NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted.

    directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be...

    Research recommendation
    Published
    9 June 2015

  2. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)

    Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    28 March 2024
    View recommendations

    Sections for TA962

  3. NICE concluded that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema secondary to retinal vein occlusion should be conducted.

    directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema secondary to retinal...

    Research recommendation
    Published
    9 June 2015

  4. Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)

    Evidence-based recommendations on cabozantinib (Cabometyx) for advanced hepatocellular carcinoma in adults who have had sorafenib.

    Technology appraisal guidance
    Published
    14 December 2022
    View recommendations

    Sections for TA849

  5. Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]

    Awaiting development Reference number: GID-TA11703 Expected publication date:  25 February 2026

    Technology appraisal guidance
    Awaiting development

  6. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

    Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    25 March 2014
    View recommendations

    Sections for TA307

  7. Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency (TA1117)

    Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency in adults.

    Technology appraisal guidance
    Published
    16 December 2025
    View recommendations

    Sections for TA1117

  8. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    14 September 2022
    View recommendations

    Sections for TA824

  9. Regorafenib for previously treated metastatic colorectal cancer (TA866)

    Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    8 February 2023
    View recommendations

    Sections for TA866

  10. Bevacizumab for treating recurrent glioblastoma [ID978]

    Discontinued Reference number: GID-TA10149

    Technology appraisal guidance
    Discontinued

  11. Bevacizumab for the treatment of recurrent glioblastoma multiforme [ID80]

    Discontinued Reference number: GID-TAG413

    Technology appraisal guidance
    Discontinued

  12. Bevacizumab for untreated malignant pleural mesothelioma [ID1183]

    Discontinued Reference number: GID-TA10197

    Technology appraisal guidance
    Discontinued

  13. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

    Awaiting development Reference number: GID-TA11538 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Past appeals and decisions

    Past technology appraisal appeals and decisions

  15. Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars

    More than 7,000 people in England will now be able to access to a life-extending treatment for advanced bowel cancer.

    News
    Last updated
    24 December 2025